Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
CBS News
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from CBS News.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
CBS News (www.cbsnews.com), a Tier B publisher, filed this report on . CurrentWire published this page 1 minute later, on .
Signal breakdown
CurrentWire ranked this story 61.8 of 100 in the snapshot this page was rendered from.
- Freshness
- 32.3 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 32.3 of 35. How each signal is calculated.
Filed under Health · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.